



Aurobindo Pharma receives tentative approval for Losartan Potassium tablets

Aurobindo Pharma Limited is pleased to announce that it has received the tentative approval to manufacture and market Losartan Potassium tablets in the strengths 25mg, 50mg and 100mg from the US Food & Drug Administration (USFDA).

Losartan Potassium tablets are the generic equivalent of Merck Research Laboratories Cozaar® Tablets 25mg, 50mg and 100mg and falls in the anti-hypertensive segment. The branded sales of Losartan range of products was USD 1235 million for the year ended December 2007 according to Merck Financial Disclosures

This is Aurobindo's 75th ANDA approval from USFDA.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. The Company is marketing these products globally, in over 100 countries..

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com